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 Abstract. The present case report was aimed at identifying
the molecular profile characteristic of a primitive neuro-
ectodermal tumor (PNET) in a 3-year-old child affected by a
lesion localized in the cerebellar region. The histological
diagnosis was medulloblastoma. In vivo single voxel 1H
magnetic resonance spectroscopy (MRS) shows high specificity
in detecting the main metabolic alterations in the primitive
cerebellar lesion; a very high amount of the choline-containing
compounds and very low level of creatine derivatives and N-
acetylaspartate. Ex vivo high resolution magic angle spinning
(HR-MAS) 1H magnetic resonance spectroscopy, performed
at 9.4 Tesla on the neoplastic specimen collected during
surgery, allows for the unambiguous identification of several
metabolites giving a more in-depth evaluation of the metabolic
pattern of the lesion. The ex vivo HR-MAS MR spectra
show that the spectral detail is much higher than that obtained
in vivo and that, for example, myo-inositol, taurine and
phosphorylethanolamine contribute to the in vivo signal at
3.2 ppm, usually attributed to choline-containing compounds.
In addition, the spectroscopic data appear to correlate with
some morphological features of the medulloblastoma.
Consequently, the present study shows that ex vivo HR-MAS
1H MRS is able to strongly improve the clinical possibility of
in vivo MRS and can be used in conjunction with in vivo
spectroscopy for clinical purposes.
Introduction
In clinical examinations, in vivo magnetic resonance
spectroscopy (MRS) is a non-invasive method to detect the
biochemical changes accompanying the disease. The clinical
impact of MRS in medicine has been widely reviewed by
Smith et al and shows promise as a method to complement
routine diagnostic investigation (1). However, the poor in vivo
spectral resolution leads to limited characterization of the real
biochemical composition of explored tissue. Moreover, even
among metabolites that are highly detectable with in vivo
MRS, subtle concentration differences between normal and
pathological tissue, such as a neoplasm, can go unnoticed and
result in a diagnostic error.
The detailed biochemical picture of tissue is the basis of
correct interpretation by in vivo MRS, which can be used when
the molecular markers are well established. A deep knowledge
of the biochemical composition of tissue can be obtained by
spectroscopic analysis on extracts obtained from tissue (in vitro
MRS) or directly from tissue specimens (ex vivo MRS). High
resolution magic angle spinning (HR-MAS) ex vivo MRS is a
powerful analytical tool for human tissue, potentially bridging
the divide between in vitro and in vivo MRS. The first
applications of HR-MAS MRS on human tissue specimens
date back to 1997 (2,3) and are possible thanks to the
commercial diffusion of MRS probe-heads capable of studying
samples in rapid rotation around an axis of 54.7˚ (‘magic
angle’), tilted with respect to that of the static magnetic field.
These probe-heads drastically reduce contributions from
dipolar couplings, chemical shift anisotropy and susceptibility
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distortions, thus providing high resolution spectra from semi-
solid samples such as tissue (4-11). The quality of the obtained
spectra is comparable to that obtained from aqueous extracts,
and the possible acquisition techniques are the same as those
employed in in vitro MRS, with the advantage of carrying
out measurements on intact tissue specimens without
pretreatment. 
We present a case where a comparison between in vivo
single voxel and ex vivo HR-MAS 1H MRS was performed
on a child affected by medulloblastoma.
Case report
Clinical material. A 3-year-old child was admitted to the
hospital because of persistent headaches, which started 1
month previously, and a refusal to eat due to persistent nausea.
He underwent magnetic resonance imaging (MRI) and in vivo
1H MRS of the head on a 1.5 Tesla clinical imager (Philips
Intera, Best, Netherlands), which revealed an intracranial tumor
occupying most of the left portion of the posterior fossa.
Compared to brain parenchyma, the lesion was predominantly
hyperintense on T2-weighted images and slightly hypointense
on T1-weighted images with restricted apparent diffusion
coefficient (ADC). After intravenous gadolinium injection,
the mass was enhanced strongly, but not uniformly due to
internal small cystic components (Fig. 1). Extension to
supratentorial space through the Pacchioni foramen was
clearly visualized, and an extra-axial subarachnoid location
was initially suggested. Compression of the fourth and third
ventricles and the aqueductus caused marked hypertensive
triventricular hydrocephalus. Spine imaging revealed diffused
leptomeningeal tumor localizations. The very large dimension
of the tumor combined with the high cellular density, as
suggested by the restricted ADC, and the apparent extra-axial
localization into the subarachnoid space, raised the diagnostic
hypotheses of a rare case of lymphoma to be differentiated
from medulloblastoma.
After MR examination, a ventricular-peritoneal shunt was
positioned. Twelve days after MRI, the child underwent brain
surgery, which revealed an intra-axial tumor. Extemporaneous
histological examination on a sample was diagnostic for
medulloblastoma and extensive, but only partial resection of
the tumor was possible.
Subsequent histopathological analysis revealed apoptotic
elements, necrosis, high proliferation activity (MIB1 =70%)
and highly positive CD56 immunoassay. No nodular aspect
was reported.
In vivo 1H MRS. In vivo 1H MR spectra were performed using
a spin-echo sequence with 144 ms echo time (TE), 2 sec
repetition time (TR), and averaging the signal of 128
consecutive scans, 512 data points and PRESS localization
technique. Two volumes of interest (VOI) (3x2x2 cm) were
placed respectively on the tumor mass (Fig. 1) and on normal-
appearing cerebellar parenchyma. Water signal suppression
was performed using a standard CHESS sequence with two
Gaussian chemical shift selective pulses of 70 Hz. The data
were processed using CSX2 (Kennedy Krieger Institute,
Baltimore, USA). DC Correction, Zero Filling factor 2,
Gaussian Filter with L.B. 3.0 Hz (time domain), High Pass
Filter Bandwith 50 Hz (to suppress water peak) and baseline
correction was applied to both the spectra data.
Ex vivo HR-MAS 1H MRS. During neurosurgery, a sample of
the medulloblastoma was put in liquid nitrogen and stored at
-85˚C until ex vivo MRS analysis. Before MRS examination,
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Figure 1. Conventional MR imaging. (a) Axial diffusion weighted; (b) apparent diffusion coefficient; (c) axial T2 weighted; (d) saggital T1 weighted;
(e) post-gadolinium sagittal T1 weighted; (f) sagittal T2 weighted; and (g) single voxel localizer displayed in green over T2 weighted axial and sagittal
images.
the sample was flushed with D2O prior to insertion in the
MAS rotor (4 mm OD). Sample and instrument preparation
took about 20 min.
Proton HR-MAS spectra were recorded with a Bruker
Avance 400 spectrometer equipped with a 1H,13C HR-MAS
probe, utilizing the sequences implemented in the Bruker
software. The sample was spun at 2800 Hz and three different
types of 1D (monodimensional) proton spectra were acquired
by using: i) a composite pulse sequence (zgcppr) (12) with
1.5 sec water-presaturation during relaxation delay, 8 kHz
spectral width, 32k data points, 32 scans; ii) a water-suppressed
spin-echo Carr-Purcell-Meiboom-Gill sequence (cpmgpr) (13)
with 1.5 sec water-presaturation during relaxation delay, 1 ms
echo time (
 
Ù) and 360 ms total spin-spin relaxation delay
(2nÙ), 8 KHz spectral width, 32k data points, 256 scans; and
iii) a sequence for diffusion measurements based on stimulated
echo and bipolar-gradient pulses (ledbpgp2s1d) (14) with big
delta 200 ms, eddy current delay Te 5 ms, little delta 2x2 ms,
sine-shaped gradient with 32 G/cm followed by a 200 µs
delay for gradient recovery, 8 kHz spectral width, 8k data
points, 256 scans. Two-dimensional 1H,1H-correlation
spectroscopy (COSY) (15,16) spectra were acquired using a
standard pulse sequence (cosygpprqf) and 0.5 sec water-
presaturation during relaxation delay, 8 kHz spectral width,
4k data points, 32 scans per increment, 256 increments.
Two-dimensional (2D) 1H,1H-total correlation spectroscopy
(TOCSY), (17,18) spectra were acquired using a standard
pulse sequence (mlevphpr) and 1 sec water-presaturation during
relaxation delay, 100 ms mixing (spin-lock) time, 4 kHz
spectral width, 4k data points, 32 scans per increment, 128
increments. Two-dimensional 1H,13C-heteronuclear single
quantum coherence (HSQC) (19) were acquired using a echo-
antiecho phase sensitive standard pulse sequence (hsqcetgp)
and 0.5 sec relaxation delay, 1.725 ms evolution time, 4 kHz
spectral width in f2, 4k data points, 128 scans per increment,
17 kHz spectral width in f1, 256 increments.
Results and Discussion
The single voxel in vivo 1H MR spectra obtained from the
medulloblastoma and contralateral healthy cerebellum are
reported in Fig. 2a and b, respectively. The spectrum of the
lesion (Fig. 2a) displays one predominant signal at 3.2 ppm,
which is usually attributed to choline-containing compounds
(ChoCC); accompanied by low intensity peaks at 3.0 ppm,
attributable to creatine derivatives (Cr); at 2.3 ppm,
attributable to glutamate plus glutamine (Glx); and at 2.0
ppm, attributable to N-acetylaspartate (NAA) and Glx (5).
The high ChoCC/Cr ratio found in the present case can be
associated with the synthesis of new cell membranes. Several
MRS studies correlate the increase of such compounds to the
cell neoplastic proliferation (20,21).
Moreover, it can be noted that signals downfield from
ChoCC are nearly absent in the MR spectrum of the lesion
with respect to that of the contralateral healthy cerebellum
(Fig. 2b). In fact, the in vivo MR spectrum of the contralateral
VOI shows high signals from NAA at 2.0 ppm, Cr at 3.0 ppm,
ChoCC at 3.2 ppm, and myo-inositol (Myo) at 3.5 ppm.
Lower signals due to NAA at 2.5 ppm and to Glx at 2.3 ppm
are also observed. The signal at 3.5 ppm could receive
contributions from both Myo and glycine (Gly). Signals at
higher frequencies are poorly resolved. ChoCC/Cr metabolite
signal intensity ratio is within the range measured for the
cerebellar tissue of healthy children, while a reduction of
NAA/ChoCC and NAA/Cr ratios is evident (20-22). We
hypothesized that the reduction of NAA was an expression of
mild oedema and neuronal dysfunction in the otherwise
normal appearing brain tissue chosen for MRS, an effect in
agreement with the high compression exerted by the tumor.
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Figure 2. In vivo 1H MR spectra of (a) medulloblastoma and (b) contralateral
healthy cerebellum.
Figure 3. HR-MAS 1H MR spectra of the medulloblastoma. (a) Conventional
1H MR spectrum obtained with water presaturation and composite pulse,
(b) CPMG spectrum obtained with 360 ms total spin-echo time and
(c) diffusion edited spectrum obtained with ¢ =200 ms, ‰ =4 ms and
gradient strength of 32 G/cm.
Fig. 3 reports the ex vivo 1H HR-MAS MR spectra of the
medulloblastoma performed with different experiments. A
conventional presaturated 1D spectrum, which highlights
both lipid and small metabolite contribution, is displayed in
panel a. Fig. 3b shows a spectrum obtained using a CPMG
spin-echo sequence [90˚- (Ù-180˚-Ù)n], in order to separate
signals according to their different T2 and enhance the
resonance of metabolites with respect to those of macro-
molecules. Fig. 3c represents the diffusion-edited spectrum
displaying contributions from mobile lipids and macro-
molecules.
The most abundant metabolites can be assigned by
comparison with literature data, but a complete assignment
requires the acquisition of selected 2D experiments such as
COSY, TOCSY and HSQC. The COSY and TOCSY spectra
are very informative for the identification of hidden resonances:
the COSY spectra enable the coupled proton-proton pairs to
be found, whereas the TOCSY spectra permit the identification
of 1H,1H connectivities of up to 5 or 6 bonds. 1H,13C HSQC
spectra permit the identification of directly bonded carbon-
proton correlations, making it possible to assign singlets
(which do not give correlations in homonuclear COSY and
TOCSY spectra), and distinguish signals from different
molecules having similar proton chemical shifts, but diverse
13C signals. These experiments enable a complete and
unambiguous identification of the metabolic pattern
characterizing the examined tissue. The principal metabolites
are labelled in Fig. 4, and the 1H and 13C assignments of the
observed pool of metabolites, particularly osmolites, free
amino acids and a fraction of mobile lipids, are reported in
Table I.
A look at the HR-MAS spectra shows that the spectral
detail is much higher than that obtainable in vivo, and that
Myo, Tau and phosphorylethanolamine (PE), and a trace of
arginine, contribute to the in vivo signal at 3.2 ppm, usually
attributed to ChoCC [glycerophosphorylcholine (GPC), phos-
phorylcholine (PC) and free choline (Cho)]. The H-5 proton
signal of Myo at 3.28 ppm (triplet) is detected through the
correlation with H-4,6 at 3.63 ppm in the COSY spectrum,
and the correlations with other protons of its spin system
(4.06, 3.63, and 3.53 ppm) in the TOCSY spectrum (Fig. 5a).
The CH2N protons of PE at 3.23 ppm (triplet) are detected in
both homonuclear correlation spectra, through a correlation
with CH2O at 4.00 ppm (a double triplet, which resembles a
quartet), which shows a coupling with the phosphorous nucleus.
Similarly, the CH2N protons of Tau at 3.26 ppm (triplet) are
detected through the correlation with CH2S at 3.42 ppm
(triplet). An estimation of relative contributions of these
metabolites to the integral value of signals between 3.32 and
3.15 ppm, usually attributed to the in vivo spectra of ChoCC,
can be derived from the evaluation of areas of selected
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Figure 4. HR-MAS 1H MR spectrum of the medulloblastoma. CPMG
spectrum obtained with 360 ms total spin-echo time; the major metabolites
are labelled.
Figure 5. Partial regions of the TOCSY MR spectrum of the medulloblastoma. The identified metabolites are denoted with labels according to Table I.
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Table I. List of the 1H and 13C chemical shift (‰, ppm) of
metabolites found in HR-MAS MR spectra of the examined
medulloblastoma.a,b
–––––––––––––––––––––––––––––––––––––––––––––––––
Metabolite ‰ 1H ‰ 13C
–––––––––––––––––––––––––––––––––––––––––––––––––
Fatty acids 0.89 14.6 CH3
1.27-1.33 23.3, 30.5 (CH2)n
1.62 CH2-C-C=O
2.02 CH2-C=
2.29 CH2C=O
2.78 =C-CH2-C=
5.32 129.6 CH=CH
Isoleucine 0.94(t) ‰-CH3
1.02(d) Á-CH3
1.29,1.48 Á-CH2
1.97 ß-CH
3.69 ·-CH
Leucine 0.95(d) 21.6 ‰-CH3
0.97(d) 22.7 ‰-CH3
1.70 24.8 Á-CH
1.72 ß-CH2
3.75 c ·-CH
Valine 0.99(d) 17.3 Á-CH3
1.04(d) 18.7 Á-CH3
2.25 ß-CH
3.61 ·-CH
Threonine 1.33(d) 20.3 Á-CH3
4.27 ß-CH
3.60 ·-CH
Lactate 1.33(d) 20.3 CH3
4.11 69.5 CH
Alanine 1.48(d) 16.8 ß-CH3
3.79 ·-CH
Lysine 3.04 39.9 Â-CH2
1.72 27.3 ‰-CH2
1.48 22.3 Á-CH2
1.91 30.6 ß-CH2
3.78 c ·-CH
Arginine 3.23 41.3 ‰-CH2
1.69 24.9 Á-CH2
1.93 28.3 ß-CH2
3.78 c ·-CH
Glutamate 2.36(t) 34.3 Á-CH2
2.06, 2.15 27.6 ß-CH2
3.77 c ·-CH
Glutamine 2.48(td) 31.7 Á-CH2
2.14 ß-CH2
3.79 c ·-CH
Proline 3.43,3.34 ‰-CH2
2.01 Á-CH2
2.34,2.07 ß-CH2
4.12 ·-CH
Aspartic acid 2.68,2.82 ß-CH2
3.90 ·-CH
Table I. Continued.
–––––––––––––––––––––––––––––––––––––––––––––––––
Metabolite ‰ 1H ‰ 13C
–––––––––––––––––––––––––––––––––––––––––––––––––
Asparagine 2.85, 2.96 ß-CH2
4.01 ·-CH
Creatine 3.04(s) 38.0 NCH3
3.92(s) 54.8 CH2
Tyrosine 3.06,3.20 ß-CH2
3.93 ·-CH
6.88 Hortho
7.20 Hmeta
Phenylalanine 7.33 Hortho
7.37 Hpara
7.43 Hmeta
Ethanolamine 3.83 CH2
3.15 CH2
Phosphoryl
ethanolamine 3.23 (t) 41.5 CH2
4.00 (dt) 61.3 CH2
Glycerophosphoryl-
ethanolamine 3.34 CH2
4.13 CH2
Choline 3.20 54.7 N(CH3)3
3.53 68.2 NCH2
4.07 OCH2
Phosphorylcholine 3.22 54.7 N(CH3)3
3.61 67.3 NCH2
4.19 58.8 OCH2
Taurine 3.26(t) 48.7 NCH2
3.42(t) 36.4 SCH2
Myoinositol 3.28(t) 75.3 5-CH
3.63(t) 73.1 4,6-CH
3.53(dd) 72.3 1,3-CH
4.06(t) 73.0 2-CH
Scyllo-inositol 3.35 (s)
Glycine 3.56 42.3 CH2
UDPG or UMPG - 5-CH2rib
4.13 4-CHrib
4.23 3-CHrib
4.36 2-CHrib
5.92 1-CHrib
5.91 5-CHur
7.89 6-CHur
Adenine 8.19 8-CH
8.23 2-CH
Acetate 1.92 CH3C=O
Unknown 8.34
–––––––––––––––––––––––––––––––––––––––––––––––––
a1H chemical shifts are referred to an alanine doublet at 1.48 ppm.
b13C chemical shifts are referred to alanine at 16.8 ppm. cC·
probably contributes to the 3.77, 55.2 ppm cross-peak.
–––––––––––––––––––––––––––––––––––––––––––––––––
signals (weighted on the basis of the relative proton numbers).
This calculation leads to the presence of 20% PE, 18% Tau,
55% PC + Cho, and 7% Myo. The same experiments highlight
a contribution from the CH2N lysine and CH2COO- asparagine
signals to the in vivo signal at 3.0 ppm, usually attributed to
NCH3 creatine protons (Fig. 5b). Creatine participates in 60%
of the total area of the region 3.10-2.90 ppm, as deduced by
comparison of the integral of the signal at 3.92 ppm (CH2
protons of creatine).
Finally, ex vivo 1H MRS experiments indicate the presence
of alanine (Ala) and lactate (Lac) and the absence of NAA.
The absence of NAA in the HR-MAS spectra and presence of
only a trace of acetate suggest that the peak at 2.0 ppm in the
in vivo spectrum could be principally due to the CH2(ß) and
CH2(Á) signals of glutamate plus glutamine.
A direct comparison between the in vivo and ex vivo MR
profiles of medulloblastoma can be made after applying a
broadening processing function to the HR-MAS signal
which, although implying the loss of a higher degree of
information furnished by the HR-MAS spectrum, shows the
close correspondence between the two spectra (Fig. 6),
especially when the region of ChoCC and Cr signals is
considered. The highest signal is that usually attributed to
ChoCC, which we have shown above to receive contributions
from a number of other metabolites, accompanied by low
intensity peaks due to glutamate plus glutamine at 2.3 and
2.0 ppm, and Cr (plus lysine and asparagine) at 3.0 ppm.
More difficult is the comparison between regions at higher
frequencies of the two spectra, where signals due to Tau,
Myo, Gly and PE are expected. These signals are evident in
the ex vivo spectrum, but they are less clear in vivo because
of more distortions from the evolution of coupling constants.
The estimation of the ratio ChoCC/Cr from the in vivo
spectrum (5/1) compares well with that from the HR-MAS
spectrum (6.5/1) obtained, considering the regions 3.15-3.32
and 3.10-2.90 ppm. Myo, Tau, Gly and PE have already been
reported as significant metabolites from in vitro MRS studies
on medulloblastoma (25,26). Accordingly, prominent Tau,
Gly and PE peaks are easily observed in our ex vivo spectrum
(Fig. 4), and the presence of Tau in in vivo spectra of the
medulloblastoma has been reported (27,28).
Further considerations can be argued from the analysis of
ex vivo MR spectra. Mobile lipids, which are already visible
in the standard presaturated 1D spectrum (Fig. 3a), are
further evidenced in the diffusion-edited spectrum (Fig. 3c)
by the broad signals at 0.89, 1.30, 3.26 and 5.32 ppm. In
particular, the 3.26 ppm resonance, deriving from the tri-
methylammonium of the choline residue, strongly suggests
that phospholipids are present in substantial amounts in the
examined medulloblastoma. It is worthwhile to underline the
presence of broad signals at 3.02 and 1.72 ppm (which are
correlated by the TOCSY experiments also to the 1.48 and
1.91 ppm signals), attributable to lysine in non-negligible
amounts and possibly involved in lysyl-phosphatidylglycerols.
These findings provide a deeper insight into the lipid
composition of brain neoplasms to be pursued. It has been
reported that the presence of mobile lipids, both in ex vivo
and in vivo MR spectra of brain neoplasms, is correlated to
necrosis in the lesions (29,30). This spectroscopic datum
directly correlates to a morphological aspect of the histo-
pathological assessment. Moreover, Tzika et al reported that
in vivo and ex vivo MR spectra of several pediatric brain
tumors exhibited substantial levels of lipids, which may be
due to apoptosis and/or necrosis (31). As a consequence, the
histological features of apoptosis and necrosis, evidenced in
the histological analysis of this medulloblastoma, are reflected
by the presence of lipid signals in our ex vivo HR-MAS MR
spectra.
In this case report, we have demonstrated that the ex vivo
HR-MAS MR spectroscopy can reach a high resolution
degree, thus providing a link between in vivo MRS and
neuropathological analysis. The present study demonstrates
that ex vivo HR-MAS 1H MRS is able to strongly improve
the clinical possibility of in vivo MRS and can be used in
conjunction with in vivo spectroscopy for clinical purposes,
in which case a large number of samples can be analyzed and
histologically classified.
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